Sustained release compositions of Trimetazidine and process for preparation thereof
Related application:
This application claims the benefit of Indian Provisional Application No.
1533/MUM/2007 filed on August 08, 2007.
Technical field of the invention:
The present invention relates to sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising:
(i) Trimetazidine or a pharmaceutically acceptable salt thereof;
(ii) at least one of the release modifying agents selected from;
(a) one or more water soluble materials;
(b) one or more water insoluble materials;
(c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients and characterized by the absence of cellulose and/or their derivatives as release modifying agents. Particularly, said compositions are in the form of solid dosage forms.
The present invention further relates to a process for preparation of said sustained release pharmaceutical compositions.
Background and Prior art:
Trimetazidine is used in the treatment of angina pectoris. Trimetazidine dihydrochloride is used therapeutically, as a coronary vasodilator for the prophylactic treatment of anginal chest pain attack and during such attacks, during chorioretinal attacks as well as for the treatment of giddiness of vascular origin. Angina pectoris, also known as angina, is chest pain due to ischemia of the heart muscle which inturn is caused due to obstruction or spasm of the coronary arteries.
Trimetazidine is chemically l-[(2,3,4-trimethoxyphenyl) methyl]piperazine with molecular formula Q4H22N2O3 and molecular weight 266.34. Trimetazidine is freely soluble in water. It has two pKa values 4.32 and 8.95. Trimetazidine regulates ionic and extra cellular exchanges, correcting the abnormal flow of ions across the cell membrane caused by ischemia and preventing cellular edema caused by anoxia. Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.
Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels but, due to the fact that it is absorbed quickly, these immediate release forms lead to maximum plasma levels immediately after administration and to a very low plasma level at the time of the next dose, resulting in great differences in peak and trough plasma levels at steady state.
Trimetazidine dihydrochloride is regarded as a safe drug in the long-term treatment of chronic ischemic disorders. A need therefore arises for compositions which could provide a sustained effect so as to achieve regular and constant plasma levels and which provides patient compliance.
There are various marketed preparations containing Trimetazidine. The brand VASTAREL from Sender is also marketed as CARDAPTAN, PREDUCTAL MR, IDAPTAN, FLAVEDON MR, TRIZEDON, VASTINAN and VASOREL. VASTAREL prolonged release film-coated tablets 35 mg contain calcium hydrogen phosphate dihydrate, hypromellose, povidone, anhydrous colloidal silica, magnesium stearate, macrogol, titanium dioxide (E171), glycerol, red iron oxide (E172).
US3262852 discloses a vasodilative substance, dihydrochloride of 1 -(2,3,4- trimethoxybenzyl) piperazine i.e. Trimetazidine dihyrochloride.
US4814176 discloses a sustained release preparation comprising: (a) chitin, chitosan, or a mixture thereof (b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and (c) pharmaceutically active agents. It however, does not provide any detailed study on Trimetazidine compositions.
EP0613686 discloses use of Trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutic use of immuno-suppressants.
CNl 864680 discloses orally disintegrated Trimetazidine hydrochloride tablet for treating angina pectoris and its process of preparation.
US3950508 discloses delayed action pharmaceutical tablets prepared from admixtures of active ingredient with talc, ethyl cellulose and magnesium stearate as tableting lubricant with twice as much talc present as ethyl cellulose.
EP0673649 discloses compositions for prolonged liberation of Trimetazidine (II) or its salts by making use of a mixture of water insoluble polymer and a plasticizer coated on a reservoir to control liberation. However, EP0673649 discloses compositions containing dose of 80mg of Trimetazidine dihydrochloride which is very high when compared to total conventional dose of 40mg to 60mg, in divided doses.
EP 1108424 discloses a matrix tablet for prolonged release of Trimetazidine where the prolonged release is controlled by the use of a cellulose derivative polymer present in the matrix, selected from hydroxypropyl cellulose, hydroxymethyl
cellulose, methyl cellulose and hydroxypropyl methyl cellulose. EP 1195160 discloses a pharmaceutical composition for sustained release of Trimetazidine dihydrochloride, comprising Trimetazidine dihydrochloride as the active substance and at least one of: (a) one or more hydrocolloid forming materials; (b) one or more hydrophobic polymers; and (c) one or more other categories of hydrophobic materials.
JP61212517 discloses a long-acting tablet of a basic water-soluble medicine, enabling the proper and slow release of the medicine independent to the pH of the gastric or intestinal juice, by using ultra fine powder of an enteric polymer base as a polymeric matrix and using hardened oil as an agent for controlling the release of the medicine.
RU2281772 discloses a medicinal formulation where the release of Trimetazidine dihydrochloride in the body from the formulation is carried out for 8 hr that provides the constant level of the preparation in blood.
WO02051417 discloses a solid pharmaceutical composition, with controlled release, obtained by hot-process thermoforming of a mixture based on polymers belonging to the polymethacrylate family and Trimetazidine or one of its pharmaceutically acceptable salts.
WO03043610 discloses compositions and process for manufacturing of pharmaceutical compositions in the form of microbeads comprising of Trimetazidine dihydrochloride and further coating of the beads with polymeric membrane to tailor the drug release characteristics enabling "once a day" dosing for 60 mg dose of Trimetazidine dihydrochloride per unit dose.
While various Trimetazidine compositions are available commercially, there still exists a need for sustained release compositions that are effective and could be
used for long term treatment of angina and with better patient compliance. Object of the Invention:
The main object of the invention is to provide sustained release pharmaceutical compositions comprising (i) Trimetazidine or a pharmaceutically acceptable salt thereof; (ii) at least one of the release modifying agents selected from; (a) one or more water soluble materials; (b) one or more water insoluble materials; (c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients.
Another object of the invention is to provide pharmaceutical compositions which are characterized by the absence of cellulose and/or their derivatives as release modifying agents.
Yet another object of the invention is to provide a process for preparation of sustained release pharmaceutical compositions.
Further object of the invention is to provide compositions, which releases Trimetazidine in a sustained and reproducible manner over a prolonged period of time to achieve a sustaining effect of Trimetazidine over 10-12 hours period after oral administration.
Further object of the invention is to provide compositions of Trimetazidine that demonstrate reliable release rate and facilitated in-vivo absorption for desired period of time.
Another object of the invention is to provide sustained release compositions which are useful for the treatment of angina pectoris and has better patient compliance.
Another object of the invention is to provide a method of treating a patient
suffering from angina pectoris, comprising administering to a patient in need thereof a therapeutically effective amount of sustained release pharmaceutical compositions as described herein.
Summary of the invention:
The present invention discloses sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising Trimetazidine; wherein the compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
According to one aspect, the present invention provides sustained release pharmaceutical compositions comprising:
(i) Trimetazidine or a pharmaceutically acceptable salt thereof;
(ii) at least one of the release modifying agents selected from;
(a) one or more water soluble materials;
(b) one or more water insoluble materials;
(c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients and characterized by the absence of cellulose and/or their derivatives as release modifying agents.
According to another aspect, the present invention provides a process for preparation of sustained release pharmaceutical compositions comprising (i) Trimetazidine or a pharmaceutically acceptable salt thereof; (ii) at least one of the release modifying agents selected from; (a) one or more water soluble materials; (b) one or more water insoluble materials; (c) one or more water swellable materials; together with suitable pharmaceutically acceptable excipients; the said process comprising the steps of : i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients;
ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients and optionally one or more release modifying agents to form a granule blend; iii. lubricating the granule blend with suitable lubricants; iv. compressing the lubricated blend to form tablets or filling the lubricated blend into hard gelatin capsules; v. further coating the compressed tablets with polymer based coating.
Brief description of the drawings:
Fig. 1 shows comparative dissolution profile of Vastarel and tablets prepared according to Example 1. Dissolution was carried out in 0.1N HCL for the first hour and then in pH 6.8 phosphate buffer.
Fig. 2 shows comparative dissolution profile of Vastarel and tablets prepared according to Example 2. Dissolution was carried out in 0.1N HCL for the first hour and then in pH 6.8 phosphate buffer.
Detailed Description:
The present invention describes sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising:
(i) Trimetazidine or a pharmaceutically acceptable salt thereof;
(ii) at least one of the release modifying agents selected from;
(a)one or more water soluble materials;
(b)one or more water insoluble materials;
(c)one or more water swellable materials; together with suitable pharmaceutically acceptable excipients and characterized by the absence of cellulose and/or their derivatives as release modifying agents.
The present invention further describes a process for preparation of said sustained
release pharmaceutical compositions. Sustained release solid dosage forms such as tablets, capsules or any other solid dosage form may be formulated using the process as described herein.
The pharmaceutical compositions of the present invention releases Trimetazidine in a sustained and reproducible manner over a prolonged period of time to achieve a sustaining effect of Trimetazidine over 10-12 hours period after oral administration.
According to one general aspect, the present invention provides sustained release pharmaceutical compositions useful for the treatment of angina pectoris comprising Trimetazidine; wherein the compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
According to one aspect of the invention, Trimetazidine is present in an amount from about 8.0% to about 50.0% by weight of the total composition.
According to a preferred aspect, Trimetazidine is present in an amount from 10.0% to 30.0% by weight of the total composition.
According to another aspect, the preferred pharmaceutically acceptable salt of Trimetazidine is Trimetazidine dihydrochloride.
In the practice of the present invention, the release modifying agents may be present in an amount from 10.0% to 80.0% by weight of the total composition.
According to one embodiment of the invention, the sustained release pharmaceutical compositions of the present invention comprises release- modifying agents that may be selected from at least one of (a) one or more water- soluble materials and/or (b)one or more water insoluble materials and/or (c) one
or more water swellable materials; wherein the said compositions are characterized by the absence of cellulose and/or cellulose derivatives as release modifying agents.
According to the present invention, the ratio of Trimetazidine to release modifying agents is in the range of about 1:0.5 to 1:10; preferably 1:1 to 1:5.
In the practice of the present invention, the water soluble materials that may be employed include, but are not limited to polyethylene oxide, sodium alginate, calcium ammonium alginate, potassium alginate, calcium alginate, propylene glycol alginate, polyvinyl alcohol, povidone, carbomer, xanthan gum, triethyl citrate or mixtures thereof. Water-soluble materials may be present in an amount from 10.0% to 80.0% by weight of the total composition. Preferably, the water- soluble materials may be present in an amount from 15.0% to 70.0% by weight of the total composition. The preferred water soluble materials being polyethylene oxide having average molecular weight 4,00,000 to 60,00,000; more preferably having average molecular weight 6,00,000 to 50,00,000.
In the practice of the present invention, the water insoluble materials that may be employed include, but are not limited to stearic acid, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, microcrystalline wax, polymethacrylate, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, hydrogenated castor oil, polyvinyl acetate, polyvinyl acetate phthalate, waxes, shellac, magnesium aluminium silicates or mixtures thereof. Kollidone SR a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone is the preferred water insoluble material. Water insoluble materials may be present in an amount from 10.0% to 80.0% by weight of the total composition. Preferably, the water insoluble materials may be present in an amount from 20.0% to 70.0% by weight of the total composition.
In the practice of the present invention, the water swellable materials that may be employed include, but are not limited to alginic acid, guar gum or mixtures thereof. Water swellable materials may be present in an amount from 10.0% to 80.0% by weight of the total composition. Preferably, the water swellable materials may be present in an amount from 20.0% to 70.0% by weight of the total composition.
According to one embodiment of the invention, the sustained release compositions of the present invention may contain release modifying agents selected from one or more water soluble material employed together with one or more water insoluble material in a weight ratio of about 10:1 to 1:10. Preferably, one or more water soluble material may be employed together with one or more water insoluble material in a weight ratio of about 10:5 to 5:10.
According to another embodiment of the invention, the sustained release compositions of the present invention may contain release modifying agents selected from one or more water swellable material employed together with one or more water insoluble material in a weight ratio of about 10:1 to 1:10. Preferably, one or more water swellable material may be employed together with one or more water insoluble material in a weight ratio of about 10:5 to 5:10.
Sustained release compositions according to the present invention contain Trimetazidine in a dose range from 20mg to 60mg. According to a preferred aspect, the sustained release compositions may contain Trimetazidine in doses such as 35mg, 60mg. Sustained release Trimetazidine compositions having dose of 35mg are recommended for twice-a-day administration in order to achieve a sustained effect of the drug.
According to one embodiment, the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine
dihydrochloride, 10.0% to 80.0% by weight of release modifying agent/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to 10.0% by weight of coating agents.
According to another embodiment, the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water soluble material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti- adherant and 2.0% to 10.0% by weight of coating agents.
According to a preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of water soluble material/(s), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
According to a more preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of polyethylene oxide, 20.0% to 60.0% by weight of lactose monohydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
According to another preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 15.0% to 70.0% by weight of xanthan gum, 20.0% to 60.0% by weight of lactose monohydrate, 2.0% to 10.0% by weight of
povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
According to one embodiment, the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water insoluble material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to 10.0% by weight of coating agents.
According to a preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride,20.0% to 70.0% by weight of water insoluble materials), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
According to a more preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 60.% by weight of polymethacrylate, 20.0% to 60.0% by weight of dicalcium phosphate dihydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 7.0% by weight of coating agents.
According to one embodiment, the sustained release pharmaceutical compositions of the present invention comprises 8.0% to 50.0% by weight of Trimetazidine dihydrochloride, 10.0% to 80.0% by weight of water swellable material/(s), 10.0% to 70.0% by weight of diluent, 1.0% to 15.0% by weight of binder, 0.1% to 5.0% by weight of lubricant, 0.1% to 5.0% by weight of anti-adherant and 2.0% to
10.0% by weight of coating agents.
According to a preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 70.0% by weight of water swellable material/(s), 20.0% to 60.0% by weight of diluent, 2.0% to 10.0% by weight of binder, 0.1% to 3.0% by weight of lubricant, 0.1% to 3.0% by weight of anti- adherant and 2.0% to 8.0% by weight of coating agents.
According to a more preferred embodiment, the sustained release pharmaceutical compositions of the present invention comprises 10.0% to 30.0% by weight of Trimetazidine dihydrochloride, 20.0% to 60.% by weight of guar gum, 20.0% to 60.0% by weight of dicalcium phosphate dihydrate, 2.0% to 10.0% by weight of povidone, 0.1% to 3.0% by weight of magnesium stearate, 0.1% to 3.0% by weight of colloidal silicon dioxide and 2.0% to 8.0% by weight of coating agents.
According to one embodiment, the process for preparation of Trimetazidine sustained release compositions comprises the steps of: i. preparing intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients and optionally one or more release modifying agents to form a granule blend; iii. lubricating the granule blend with suitable lubricants; iv. compressing the lubricated blend to form tablets; v. coating the compressed tablets with polymer based coating.
According to one embodiment, the process for preparation of Trimetazidine
sustained release compositions comprises the steps of: i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients and optionally one or more release modifying agents to form a granule blend; iii. mixing the intra-granular composition with extra granular composition to form a granule blend; iv. lubricating the granule blend with suitable lubricants; v. filling the lubricated blend into hard gelatin capsules;
In the practice of the present invention, the intra-granular composition is prepared by the process comprising the steps of:
(a) mixing Trimetazidine dihydrochloride and diluents with one or more release modifying agents to form a blend;
(b) preparing the binder solution by dissolving the binder in a suitable solvent;
(c) granulating the blend with the binder solution to form desired wet mass;
(d) screening the wet mass to form granules;
(e) drying the granules till 'loss on drying' value in the range of 1.0% to 7.0% is achieved;
(f) sizing the dried granules.
According to another embodiment, the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing the intra-granular composition comprising multi-particulates by extrusion or spheronisation of Trimetazidine, release modulating agents and diluents; ii. mixing the intra-granular composition with extra-granular composition
comprising suitable pharmaceutically acceptable excipients and optionally release modifying agents to form a granule blend; iii. further lubricating the granule blend; iv. compressing the lubricated blend into tablets; v. coating the compressed tablets.
According to another embodiment, the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing the intra-granular composition by granulating Trimetazidine dihydrochloride with release modifying agents by hot melt granulation or by extrusion; ii. mixing the intra-granular composition with extra-granular composition comprising suitable pharmaceutically acceptable excipients to form granule blend; iii. further lubricating the granule blend; iv. compressing the lubricated blend into tablets; v. coating the compressed tablets.
According to another embodiment, the process of preparation of Trimetazidine compositions comprises the steps of: i. preparing an intra-granular composition of Trimetazidine dihydrochloride, release modifying agent/(s) and suitable pharmaceutically acceptable excipients; ii. mixing the intra-granular composition with extra granular composition comprising suitable pharmaceutically acceptable excipients to form granule blend; iii. lubricating the granule blend with lubricants; iv. compressing the lubricated blend into minitablet; v. coating the mini-tablets with/without release modifying agent and suitable pharmaceutically acceptable excipients.
vi. mixing the coated mini-tablets with suitable pharmaceutical acceptable excipients and finally compressing into tablets vii. coating the compressed tablets.
Another embodiment of the invention is to provide a method of treating a patient suffering from angina pectoris, comprising administering to a patient in need thereof a therapeutically effective amount of sustained release pharmaceutical compositions as described herein.
Further, the compositions of the present invention provide a reliable in vitro- dissolution profile for sustained effect of Trimetazidine.
Suitable pharmaceutically acceptable excipients that can be used for formulation include, but are not limited to, diluents/fillers, binders, anti-adherants, lubricants, and the like.
Diluents that may be used as per the invention include, but are not limited to dihydrogen calcium phosphate, tribasic calcium phosphate, calcium carbonate, lactose, microcrystalline cellulose or mixtures thereof and are present in an amount from 10% to 70% by weight of the total composition.
Binders that may be used as per the invention include, but are not limited to polyvinylpyrrolidone, gelatin, polyvinyl alcohol, gum acacia and the like and is present in an amount 1.0% to 15% by weight of the total composition.
Solvents that may be used as per the invention include isopropyl alcohol, water or mixtures thereof in an amount sufficient to dissolve the binder.
Anti-adherents that may be used as per the invention include, but are not limited to colloidal silicon dioxide, talc, starch and the like and are present in an amount
from 0.1% to 5.0% by weight of the total composition.
Lubricants that may be used as per the invention include, but are not limited to magnesium stearate, calcium stearate, zinc stearate and the like and is present in an amount from 0.1% to 5.0% by weight of the total composition.
Sustained release compositions prepared by the process as described herein is further film coated using any of the conventional coating techniques known in the prior art like pan coating, spray coating etc. Tablet coat of 2%-10% with respect to total weight may be employed to have desired release.
Functional coating may be carried out using release modifying agents (functional coating polymers) other than cellulose and/or cellulose derivatives. Functional coating polymers may be selected from polymethacrylates, polyvinylacetate phthalates, polyvinyl acetate and the like.
Non-functional film coating may be carried out using one or more excipients selected from the group comprising film formers, opacifiers, coating agents, taste- masking agents, colouring agents, antitacking agents and the like. Film formers such as hydroxypropyl cellulose or hydroxypropyl methylcellulose or the like may be used. Opacifying agents that may be used include titanium dioxide, ferric oxide, sunset yellow and the like. Plasticizers such as polyethylene derivatives, polyethylene glycol, propylene glycol, triethyl citrate and the like may be used. Antitacking agents include talc, stearic acid, magnesium stearate, colloidal silicon dioxide and the like. Excipients for non-functional film coating may be used in concentrations which are well known to a person skilled in the art. Non-functional film coating serves the purpose of taste neutralization and provides elegance to the tablets.
The pharmaceutical compositions of the present invention are stable physically as
well as chemically at accelerated conditions of stability.
The sustained release compositions of the present invention shows the following in- vitro drug release characteristics when tested in 0.1N HCl for the first hour and then in phosphate buffer pH 6.8; which is comparable to the dissolution profile of Vastarel tablets.
As used herein, the term "release modifying agent" refers to formulation excipients that sustain the release of the drug from the dosage form.
As used herein, the term "excipients" refers to a pharmaceutically acceptable ingredient that is commonly used in the pharmaceutical technology for preparing granules and/or solid oral dosage compositions.
As used herein, the term "tablet" refers and is intended to encompass compressed pharmaceutical dosage formulations of all shapes and sizes, whether coated or uncoated.
As used herein, the terms "comprise," "comprising," and "include" are intended to be open, non-limiting terms, unless the contrary is expressly indicated.
The present invention is further illustrated by reference to the following examples, which does not limit the scope of the invention in any way. It will be apparent to those skilled in the art that many modifications, both to the materials and methods, can be practiced without departing from the purpose and scope of the disclosure.
Examples
Example 1
Trimetazidine dihydrochloride (175 gm), lactose monohydrate (359 gm) and polyethylene oxide (Polyox WSR N303) (150 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (30 gm) dissolved in isopropyl alcohol (675 gm). The resultant mass was dried at 600C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
Example 2
Trimetazidine dihydrochloride (175 gm), lactose monohydrate (400.5gm) and xanthan gum (400 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (37.5gm) dissolved in isopropyl alcohol (215 gm). Resultant mass was dried at 600C and agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (6.0 gm) and magnesium stearate (6.0 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
Example 3
Trimetazidine dihydrochloride (175 gm), dicalcium phosphate dihydrate (388 gm) and polymethacrylate (Eudragit RSPO) (150 gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (50 gm) dissolved in
isopropyl alcohol (596 gm). Resultant mass was dried at 600C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (6.0 gm) and magnesium stearate (6.0 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
Example 4
Trimetazidine dihydrochloride (175 gm) and dicalcium phosphate dihydrate (354gm) were mixed and granulated using binder solution containing polyvinyl pyrrolidone (25 gm) dissolved in isopropyl alcohol (115 gm). Resultant mass was dried at 600C and agglomerates were milled to required size. Sized granules were blended with Kollidone SR (560gm) (Kollidone SR is a physical mixture of polyvinyl acetate and polyvinyl pyrrolidone), colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
Example 5
Trimetazidine dihydrochloride (175 gm), dicalcium phosphate dihydrate (584gm) and polyvinyl pyrrolidone (30 gm) were mixed and granulated using binder solution containing polyvinyl alcohol (250 gm) dissolved in water (475 gm). Resultant mass was dried at 600C and the agglomerates were milled to required size. Sized granules were blended with colloidal silicon dioxide (5.5 gm) and magnesium stearate (5.5 gm). Compressed the blended granules into tablets. Finally tablets were coated using non functional coating composition.
Example 6
Glyceryl monostearate (116.67 gm) was melted at 600C. Trimetazidine dihydrochloride (175 gm) and lactose monohydrate (300gm) were mixed and heated to 600C in a jacketed rapid mixer granulator and granulated with the melted stearate at 600C. After granulation the granulated mass was mixed continuously
till it cools to room temperature. Shellac (29.77 gm) and polyvinyl pyrrolidine (14.58 gm) were dissolved in isopropyl alcohol (73 gm). This solution was gradually added to the above granulated mass and the resultant mass was dried at 450C and then milled to required size. Sized granules were blended with colloidal silicon dioxide (3.0 gm) and magnesium stearate (6.0 gm). Compressed the blended granules into tablets. Finally the tablets were coated using non functional coating composition.
In-vitro dissolution study
In- vitro dissolution rate studies of the Trimetazidine tablets prepared according to Example 1 of the present invention and which when tested in 0.1N HCl for the first hour and then in phosphate buffer pH 6.8. shows the results as shown in Table 1.
Table 1
In- vitro dissolution rate studies of the Trimetazidine tablets prepared according to Example 2 of the present invention and which when tested in 0.1N HCl for the first hour and then in phosphate buffer pH 6.8. shows the results as shown in Table 2.
Table 2
Bioequivalence study
A bioequivalence study was conducted on healthy, adult, human subjects under fasted and fed conditions.
AUCo-t = Area under the plasma concentration versus time curve, from time zero to the last measurable concentration.
AUCo-inf = Area under the plasma concentration versus time curve, from time zero to infinity.
Cmax — maximum plasma concentration.
Example 1 is bio-equivalent to reference product (Vastarel) when tested in-vivo on healthy, adult, human subjects under fasted and fed conditions. Results on in-vivo study of compositions prepared according to Example 1 is as shown in Table 3.
Table 3
Example 2 is bio-equivalent to reference product (Vastarel) when tested in-vivo on healthy, adult, human subjects under fasted and fed conditions. Results on in-vivo study of compositions prepared according to Example 2 is as shown in Table 4.
Table 4
While the present invention is described above in connection with preferred or illustrative embodiments, these embodiments are not intended to be exhaustive or limiting of the invention. Rather, the invention is intended to cover all alternatives, modifications and equivalents included within its spirit and scope, as defined by the appended claims.